Outcome of patients with transformed indolentnon-Hodgkin lymphoma referred for autologousstem-cell transplantation

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1603-1609

  Villa, D ^a   Crump, M ^a   Keating, A ^a   Panzarella, T ^b   Feng, B ^b   Kuruvilla, J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autologous transplant; Rituximab; Transformed lymphoma

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PLATINUM DERIVATIVE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AGGRESSIVE HISTOLOGY B CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TRANSFORMED INDOLENT NONHODGKIN LYMPHOMA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 84878432447     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt029     Document Type: Article

References (34)

1. Al-Tourah AJ, Gill KK, Chhanabhai M et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26(32): 5165-5169.
2. Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15(4): 1587-1594.
3. Montoto S, Davies AJ, Matthews J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25(17): 2426-2433.
4. Conconi A, Ponzio C, Lobetti-Bodoni C et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012; 157 (2): 188-196.
5. Gine E, Montoto S, Bosch F et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17(10): 1539-1545.
6. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(5 Suppl. 5): 75-88.
7. Yuen AR, Kamel OW, Halpern J et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13(7): 1726-1733.
8. Eide MB, Lauritzsen GF, Kvalheim G et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011; 152(5): 600-610.
9. Chen CI, Crump M, Tsang R et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001; 113(1): 202-208.
10. Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19(3): 727-735.
11. Ramadan KM, Connors JM, Al-Tourah A et al. Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma. Blood 2008; 112(11): 4459.
12. Sabloff M, Atkins HL, Bence-Bruckler I et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13(8): 956-964.
13. Friedberg JW, Neuberg D, Gribben JG et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5(4): 262-268.
14. Foran JM, Apostolidis J, Papamichael D et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998; 9(8): 865-869.
15. Andreadis C, Schuster SJ, Chong EA et al. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant 2005; 36(11): 955-961.
16. Ban-Hoefen M, Kelly JL, Bernstein SH et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 2012; 53(5): 830-835.
17. Villa D, Savage KJ, Crump M et al. Autologous and allogeneic stem cell transplantation for transformed indolent non-Hodgkin lymphoma: a report of the Canadian Blood and Marrow Transplant Group (CBMTG). Ann Oncol 2011; 22 (Suppl. 4): iv115.
18. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25(15): 1986-1992.
19. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106(12): 3725-3732.
20. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105(4): 1417-1423.
21. Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112(13): 4824-4831.
22. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377(9759): 42-51.
23. van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28(17): 2853-2858.
24. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23(18): 4117-4126.
25. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19): 3121-3127.
26. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9(2): 105-116.
27. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-391.
28. Tan D, Rosenberg SA, Lavori P et al. Improved prognosis after histologic transformation (HT) of follicular lymphoma: the Stanford experience 1960-2003. Ann Oncol 2008; 19(Suppl. 4): iv111.
29. Al-Tourah AJ, Savage KJ, Gill KK et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood 2007; 110(11): 790.
30. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17 (4): 1244.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
32. Bains P, Al Tourah A, Campbell BA et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 2013; 24(2): 428-432.
33. Vellenga E, van Putten WL, van't Veer MB et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111(2): 537-543.
34. Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28(27): 4184-4190.